Search hospitals > Illinois > Kewanee

Illinois CancerCare-Kewanee Clinic

Claim this profile
Kewanee, Illinois 61443
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Stomach Cancer
Conducts research for Non-Small Cell Lung Cancer
376 reported clinical trials
2 medical researchers
Photo of Illinois CancerCare-Kewanee Clinic in KewaneePhoto of Illinois CancerCare-Kewanee Clinic in KewaneePhoto of Illinois CancerCare-Kewanee Clinic in Kewanee

Summary

Illinois CancerCare-Kewanee Clinic is a medical facility located in Kewanee, Illinois. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Stomach Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Kewanee Clinic is involved with conducting 376 clinical trials across 484 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.

Area of expertise

1Skin Cancer
Global Leader
Illinois CancerCare-Kewanee Clinic has run 143 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Breast Cancer
Global Leader
Illinois CancerCare-Kewanee Clinic has run 64 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Illinois CancerCare-Kewanee Clinic

Lung Cancer
Skin Cancer
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Breast cancer
Ovarian Cancer
Multiple Myeloma
Stomach Cancer
Pancreatic Cancer
Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Illinois CancerCare-Kewanee Clinic?
Where is Illinois CancerCare-Kewanee Clinic located?
Who should I call to ask about financial aid or insurance network?
What insurance does Illinois CancerCare-Kewanee Clinic accept?
What awards or recognition has Illinois CancerCare-Kewanee Clinic received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security